MedTrace Logo

Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients

NCT06901609 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-03-30

No results posted yet for this study

Summary

Heart failure with reduced ejection fraction (HFrEF) is a significant cause of morbidity and mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated efficacy in improving renal outcomes in patients with HFrEF. Pharmacogenetics, the study of how genetic variations influence drug response, could elucidate inter-individual variability in treatment outcomes. This study aims to assess the impact of specific genetic variants on renal outcomes in HFrEF patients treated with SGLT2 inhibitors.

Conditions

  • Heart Failure - NYHA II - IV
  • Cardiac Fibrosis
  • Cardiac Remodeling

Interventions

DRUG

SGLT2 inhibitor (Dapagliflozin 10mg)

Renal response after 6 months of Dapagliflozin therapy among patients with heart failure reduced ejection fraction.

Sponsors & Collaborators

  • National Heart Institute in Egypt

    collaborator UNKNOWN

  • Misr International University

    collaborator OTHER

  • Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

    collaborator UNKNOWN

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Bassem Zarif, MD · National Heart Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-22
Primary Completion
2025-06-01
Completion
2025-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06901609 on ClinicalTrials.gov